More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZFive years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by Share XMore to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZhttps://pharmaphorum.com/news/more-to-come-from-parp-drugs-says-biotech-ceo-after-striking-radiotherapy-deal-with-az/
